The direct thrombin inhibitor melagatran/ximelagatran-Reference-Cited by-同舟云学术

The direct thrombin inhibitor melagatran/ximelagatran

Published:2005-03 Issue:5 Volume:182 Page:254-255
ISSN:0025-729X
Container-title:Medical Journal of Australia
language:en
Short-container-title:Medical Journal of Australia

Author:

Bereznicki Luke R¹,Jackson Shane L¹,Peterson Gregory M¹

Affiliation:

1. Unit for Medication Outcomes Research and Education, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001.

Publisher

AMPCo

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.5694/j.1326-5377.2005.tb06686.x

Reference7 articles.

1. The direct thrombin inhibitor melagatran/ximelagatran

2. Controversial: oral thrombin inhibitor ximelagatran (exanta). Available at:www.arznei‐telegramm.de/journal/j_0407_a.html(accessed Dec2004).

3. US Food and Drug Administration: Statistical review and evaluation‐clinical studies (Exanta 36 mg bid oral formulation). Available at:www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4069b1.htm(accessed Dec2004).

4. Australian Institute of Health and Welfare.Australian hospital statistics 2002–03. Available at:www.aihw.gov.au/publications/index.cfm/title/10015(accessed Dec 2004).

5. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letters to the Editor;Journal of Pharmacy Practice and Research;2006-06

2. The risks of warfarin use in the elderly;Expert Opinion on Drug Safety;2006-04-13